Partial characterization of a novel endogenous opioid in human cerebrospinal fluid.
Human cerebrospinal fluid (CSF) contains many uncharacterized endogenous opioids, in addition to the known enkephalins, endorphins, and dynorphins. These opioids may be separated by gel filtration chromatography and identified by radioreceptor assay for opioid activity. One region of the chromatographic elution profile, designated "Peak B" has previously been shown to be related to the pain status of chronic pain patients. We now report that human Peak B isolated from the CSF of pain-free elective surgery patients is present at a typical concentration equivalent in activity to 1.4 pmol of morphine sulfate per ml of CSF measured by radioreceptor assay. At a dose of 0.06 and 0.12 pmol morphine sulfate equivalents of CSF (MSE), injected into the cerebroventricular system of the mouse, Peak B produced an antinociceptive effect, the intensity and duration of which was dose-dependent and which was antagonized by naloxone. The mouse vas deferens (MVD) preparation was inhibited by Peak B in a manner that was sensitive to antagonism by naloxone only at low (less than 1.0 microM) but not at higher (greater than 6.0 microM) concentrations of the antagonist. Peak B activity in the MVD assay was unaffected by treatment with trypsin or alpha-chymotrypsin.
Miller
B E
BE
Department of Biochemistry, University of Tennessee Center for Health Sciences, Memphis 38163.
Lipman
J J
JJ
Byrne
W L
WL
D000818:Animals; D002850:Chromatography, Gel; D002918:Chymotrypsin; D004723:Endorphins / Q000134:cerebrospinal fluid* / Q000302:isolation & purification / Q000494:pharmacology; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D010146:Pain / Q000188:drug therapy; D011869:Radioligand Assay; D014357:Trypsin; D014649:Vas Deferens / Q000187:drug effects
D004723:Endorphins; D002918:Chymotrypsin; D014357:Trypsin